Natriumoxibat Kalceks (Sodium Oxybate)

Sodium Oxybate acts as an agonist at GHB receptors and modulates GABA_B receptors in the brain. This dual activity reduces neuronal firing, promotes slow‑wave sleep, and stabilises muscle tone, which together alleviate cataplexy and improve overall sleep architecture in narcolepsy.

The specific dose of Natriumoxibat Kalceks is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage regimens are tailored during treatment initiation and may be adjusted over time under medical supervision.

Safety data for Sodium Oxybate in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed after careful consideration by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Unlike stimulant agents such as modafinil, Sodium Oxybate uniquely targets cataplexy by enhancing slow‑wave sleep and stabilising muscle tone. It is the only medication approved specifically for cataplexy, whereas other therapies primarily address excessive daytime sleepiness without directly reducing cataplectic episodes.

Store Natriumoxibat Kalceks at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually in divided doses taken at night under medical supervision. It is important to follow the prescriber’s instructions regarding timing and any required fasting or fluid intake to ensure optimal absorption and effect.

The most critical risks include respiratory depression, severe hypotension, seizures, and the potential for abuse or dependence due to its GHB activity. Patients should be monitored closely for signs of these serious adverse events, especially during dose titration.

Individuals with severe respiratory disorders, known hypersensitivity to Sodium Oxybate, or a history of substance abuse should avoid this medication. It is also contraindicated in patients who are unable to safely monitor their breathing or who are taking prohibited concomitant CNS depressants.